Medicamen Organics Ltd
Incorporated in 1995, Medicamen Organics Ltd develops, manufactures, and distributes a broad range of pharmaceutical dosages including generic dosage[1]
- Market Cap ₹ 32.3 Cr.
- Current Price ₹ 27.6
- High / Low ₹ 60.6 / 19.6
- Stock P/E 9.87
- Book Value ₹ 25.4
- Dividend Yield 0.00 %
- ROCE 14.1 %
- ROE 14.5 %
- Face Value ₹ 10.0
Pros
- Stock is trading at 1.09 times its book value
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company might be capitalizing the interest cost
- Company has high debtors of 244 days.
- Working capital days have increased from 62.1 days to 138 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Half Yearly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| 31.49 | 25.05 | 20.98 | 22.15 | 25.27 | 37.09 | |
| 30.14 | 23.41 | 19.78 | 20.29 | 20.53 | 31.53 | |
| Operating Profit | 1.35 | 1.64 | 1.20 | 1.86 | 4.74 | 5.56 |
| OPM % | 4.29% | 6.55% | 5.72% | 8.40% | 18.76% | 14.99% |
| 0.09 | 0.01 | 0.21 | 0.82 | 1.07 | 0.10 | |
| Interest | 0.46 | 0.48 | 0.47 | 0.61 | 0.65 | 0.54 |
| Depreciation | 0.77 | 0.68 | 0.68 | 0.71 | 0.72 | 0.74 |
| Profit before tax | 0.21 | 0.49 | 0.26 | 1.36 | 4.44 | 4.38 |
| Tax % | 47.62% | 40.82% | 61.54% | 28.68% | 40.77% | 25.34% |
| 0.10 | 0.30 | 0.09 | 0.97 | 2.62 | 3.27 | |
| EPS in Rs | 0.17 | 0.50 | 0.15 | 1.62 | 3.05 | 2.79 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 3% |
| 3 Years: | 21% |
| TTM: | 47% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 101% |
| 3 Years: | 231% |
| TTM: | 64% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | -48% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 11% |
| 3 Years: | 15% |
| Last Year: | 15% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| Equity Capital | 6.00 | 6.00 | 6.00 | 6.00 | 8.60 | 11.70 |
| Reserves | 1.11 | 1.47 | 1.56 | 2.98 | 6.66 | 18.02 |
| 8.27 | 9.59 | 10.24 | 11.79 | 12.66 | 12.13 | |
| 10.44 | 9.28 | 9.27 | 11.82 | 10.52 | 15.60 | |
| Total Liabilities | 25.82 | 26.34 | 27.07 | 32.59 | 38.44 | 57.45 |
| 11.28 | 11.35 | 11.29 | 10.87 | 10.35 | 10.13 | |
| CWIP | 0.06 | 0.00 | 0.00 | 0.00 | 0.15 | 2.22 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.27 |
| 14.48 | 14.99 | 15.78 | 21.72 | 27.94 | 44.83 | |
| Total Assets | 25.82 | 26.34 | 27.07 | 32.59 | 38.44 | 57.45 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| 1.58 | -1.16 | 0.04 | -0.58 | -3.66 | -4.91 | |
| -0.45 | -0.02 | -0.59 | -0.28 | -0.34 | -2.62 | |
| -0.55 | 1.27 | 0.18 | 0.94 | 4.01 | 10.25 | |
| Net Cash Flow | 0.58 | 0.09 | -0.37 | 0.07 | 0.01 | 2.72 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| Debtor Days | 63.98 | 109.72 | 108.73 | 177.47 | 241.21 | 243.56 |
| Inventory Days | 101.47 | 61.22 | 128.47 | 225.01 | 244.39 | 228.39 |
| Days Payable | 225.45 | 161.56 | 198.97 | 329.82 | 281.81 | 355.85 |
| Cash Conversion Cycle | -60.01 | 9.38 | 38.24 | 72.66 | 203.80 | 116.10 |
| Working Capital Days | -51.00 | -47.06 | -45.41 | -25.71 | 74.24 | 137.77 |
| ROCE % | 5.98% | 4.19% | 10.22% | 16.59% | 14.10% |
Documents
Announcements
-
Certificate under SEBI (Depositories and Participants) Regulations, 2018
16 October 2025 - Reconciliation of share capital audit for quarter ended Sep 30, 2025; issued by Anu Malhotra & Associates.
-
Certificate under SEBI (Depositories and Participants) Regulations, 2018
15 October 2025 - KFin certifies Regulation 74(5) compliance for quarter ended September 30, 2025.
-
Trading Window
29 September 2025 - Medicamen Organics trading window closed Oct 1, 2025 until 48 hours after board meeting approving H1 Sep 30, 2025 results.
-
Shareholders meeting
26 September 2025 - 30th AGM Sept 25, 2025: both resolutions passed unanimously with 7,622,000 votes in favour.
-
Shareholders meeting
25 September 2025 - 30th AGM on Sept 25, 2025: adopted FY2024-25 financials; reappointed Bal Kishan Gupta.
Annual reports
Concalls
-
Jun 2025Transcript PPT
-
Nov 2024Transcript PPT
-
Oct 2024TranscriptNotesPPT
-
Jun 2024TranscriptNotesPPTREC
Business Overview:[1][2]
MOL specializes in manufacturing and distributing tablets, capsules, syrups, and ointments. It offers B2B contract and third-party manufacturing services for pharma companies in India and globally. Its portfolio includes generic and branded formulations, catering to government sectors, private institutions, and prominent pharma firms. Products are marketed via third-party distributors and loan licensing agreements.